Eliane Rohner1, Fabio Valeri, Mhairi Maskew, Hans Prozesky, Helena Rabie, Daniela Garone, Diana Dickinson, Cleophas Chimbetete, Priscilla Lumano-Mulenga, Izukanji Sikazwe, Natascha Wyss, Kerri M Clough-Gorr, Matthias Egger, Benjamin H Chi, Julia Bohlius. 1. *Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland; †Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ‡Division of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; §Department of Pediatrics and Child Health, University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; ‖Khayelitsha ART Program, Medecins Sans Frontieres, Cape Town, South Africa; ¶Independent Surgery, Gaborone, Botswana; #Newlands Clinic, Harare, Zimbabwe; **Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia; ††Boston University School of Medicine, Section of Geriatrics, Boston, MA, USA; and ‡‡Centre for Infectious Disease Epidemiology and Research (CIDER), University of Cape Town, Cape Town, South Africa.
Abstract
BACKGROUND: The risk of Kaposi sarcoma (KS) among HIV-infected persons on antiretroviral therapy (ART) is not well defined in resource-limited settings. We studied KS incidence rates and associated risk factors in children and adults on ART in Southern Africa. METHODS: We included patient data of 6 ART programs in Botswana, South Africa, Zambia, and Zimbabwe. We estimated KS incidence rates in patients on ART measuring time from 30 days after ART initiation to KS diagnosis, last follow-up visit, or death. We assessed risk factors (age, sex, calendar year, WHO stage, tuberculosis, and CD4 counts) using Cox models. FINDINGS: We analyzed data from 173,245 patients (61% female, 8% children aged <16 years) who started ART between 2004 and 2010. Five hundred and sixty-four incident cases were diagnosed during 343,927 person-years (pys). The overall KS incidence rate was 164/100,000 pys [95% confidence interval (CI): 151 to 178]. The incidence rate was highest 30-90 days after ART initiation (413/100,000 pys; 95% CI: 342 to 497) and declined thereafter [86/100,000 pys (95% CI: 71 to 105), >2 years after ART initiation]. Male sex [adjusted hazard ratio (HR): 1.34; 95% CI: 1.12 to 1.61], low current CD4 counts (≥500 versus <50 cells/μL, adjusted HR: 0.36; 95% CI: 0.23 to 0.55), and age (5-9 years versus 30-39 years, adjusted HR: 0.20; 95% CI: 0.05 to 0.79) were relevant risk factors for developing KS. INTERPRETATION: Despite ART, KS risk in HIV-infected persons in Southern Africa remains high. Early HIV testing and maintaining high CD4 counts is needed to further reduce KS-related morbidity and mortality.
BACKGROUND: The risk of Kaposi sarcoma (KS) among HIV-infectedpersons on antiretroviral therapy (ART) is not well defined in resource-limited settings. We studied KS incidence rates and associated risk factors in children and adults on ART in Southern Africa. METHODS: We included patient data of 6 ART programs in Botswana, South Africa, Zambia, and Zimbabwe. We estimated KS incidence rates in patients on ART measuring time from 30 days after ART initiation to KS diagnosis, last follow-up visit, or death. We assessed risk factors (age, sex, calendar year, WHO stage, tuberculosis, and CD4 counts) using Cox models. FINDINGS: We analyzed data from 173,245 patients (61% female, 8% children aged <16 years) who started ART between 2004 and 2010. Five hundred and sixty-four incident cases were diagnosed during 343,927 person-years (pys). The overall KS incidence rate was 164/100,000 pys [95% confidence interval (CI): 151 to 178]. The incidence rate was highest 30-90 days after ART initiation (413/100,000 pys; 95% CI: 342 to 497) and declined thereafter [86/100,000 pys (95% CI: 71 to 105), >2 years after ART initiation]. Male sex [adjusted hazard ratio (HR): 1.34; 95% CI: 1.12 to 1.61], low current CD4 counts (≥500 versus <50 cells/μL, adjusted HR: 0.36; 95% CI: 0.23 to 0.55), and age (5-9 years versus 30-39 years, adjusted HR: 0.20; 95% CI: 0.05 to 0.79) were relevant risk factors for developing KS. INTERPRETATION: Despite ART, KS risk in HIV-infectedpersons in Southern Africa remains high. Early HIV testing and maintaining high CD4 counts is needed to further reduce KS-related morbidity and mortality.
Authors: M P Carrieri; C Pradier; P Piselli; M Piche; E Rosenthal; P Heudier; J Durant; Diego Serraino Journal: Int J Cancer Date: 2003-01-01 Impact factor: 7.396
Authors: Lisa M Butler; Willy A Were; Steven Balinandi; Robert Downing; Sheila Dollard; Torsten B Neilands; Sundeep Gupta; George W Rutherford; Jonathan Mermin Journal: J Infect Dis Date: 2011-01-26 Impact factor: 5.226
Authors: B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti Journal: JAMA Date: 1999-12-15 Impact factor: 56.272
Authors: Julia Bohlius; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Daniela Garone; Mazvita Sengayi; Matthew P Fox; Mary-Ann Davies; Matthias Egger Journal: Int J Cancer Date: 2014-05-02 Impact factor: 7.396
Authors: Lukas Fenner; Stewart E Reid; Matthew P Fox; Daniela Garone; Maureen Wellington; Hans Prozesky; Marcel Zwahlen; Michael Schomaker; Gilles Wandeler; Nzali Kancheya; Andrew Boulle; Robin Wood; German Henostroza; Matthias Egger Journal: Trop Med Int Health Date: 2012-11-30 Impact factor: 2.622
Authors: Mhairi Maskew; A Patrick Macphail; Denise Whitby; Matthias Egger; Carole L Wallis; Matthew P Fox Journal: Infect Agent Cancer Date: 2011-11-17 Impact factor: 2.965
Authors: Chris A Rees; Elizabeth M Keating; Heather Lukolyo; Heather E Danysh; Michael E Scheurer; Parth S Mehta; Joseph Lubega; Jeremy S Slone Journal: Pediatr Blood Cancer Date: 2016-04-15 Impact factor: 3.167
Authors: Mina C Hosseinipour; Minhee Kang; Susan E Krown; Aggrey Bukuru; Triin Umbleja; Jeffrey N Martin; Jackson Orem; Catherine Godfrey; Brenda Hoagland; Noluthando Mwelase; Deborah Langat; Mulinda Nyirenda; John MacRae; Margaret Borok; Wadzanai Samaneka; Agnes Moses; Rosie Mngqbisa; Naftali Busakhala; Otoniel Martínez-Maza; Richard Ambinder; Dirk P Dittmer; Mostafa Nokta; Thomas B Campbell Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Robert Dubrow; Li Qin; Haiqun Lin; Raúl U Hernández-Ramírez; Romain S Neugebauer; Wendy Leyden; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Sharada P Modur; Gypsyamber DʼSouza; Ronald J Bosch; Surbhi Grover; Michael A Horberg; Mari M Kitahata; Angel M Mayor; Richard M Novak; Charles S Rabkin; Timothy R Sterling; James J Goedert; Amy C Justice; Eric A Engels; Richard D Moore; Michael J Silverberg Journal: J Acquir Immune Defic Syndr Date: 2017-08-01 Impact factor: 3.731
Authors: Salum J Lidenge; For Yue Tso; Owen Ngalamika; John R Ngowi; Yasaman Mortazavi; Eun Hee Kwon; Danielle M Shea; Veenu Minhas; Julius Mwaiselage; Charles Wood; John T West Journal: J Infect Dis Date: 2019-04-08 Impact factor: 5.226
Authors: Marie-Josèphe Horner; Steady Chasimpha; Adrian Spoerri; Jessie Edwards; Julia Bohlius; Hannock Tweya; Petros Tembo; Franklin Nkhambule; Eddie Moffo Phiri; William C Miller; Kennedy Malisita; Sam Phiri; Charles Dzamalala; Andrew F Olshan; Satish Gopal Journal: Clin Infect Dis Date: 2019-08-16 Impact factor: 9.079
Authors: Kay L Crabtree; Janet M Wojcicki; Veenu Minhas; Chipepo Kankasa; Charles Mitchell; Charles Wood Journal: J Infect Dis Date: 2017-10-17 Impact factor: 5.226